Market Performance: Sudeep Pharma Share Price Today
Sudeep Pharma's share price delivered a powerful listing today, and the Indian stock market felt that energy the moment the clock hit the opening bell. The stock entered the market with solid momentum, reflecting the high interest this IPO had already drawn.
On the NSE, Sudeep Pharma's share price opened at ₹730, marking a 23.10% premium over its IPO price.
On the BSE, it listed at ₹725, a 22.26% premium.
This is far above its issue price band of ₹563–₹593, giving the freshly listed company its moment in the spotlight.
Post-listing, Sudeep Pharma’s valuation climbed to a market capitalisation of ₹8,188.78 crore, setting the tone for a strong day in the Indian stock market.
Sudeep Pharma IPO Listing: A Debut Fueled by Heavy Demand
There was a build-up of buzz around the Sudeep Pharma IPO even before today’s listing. The public issue had drawn remarkable attention during its bidding phase between November 21 and 25, and today’s listing seems to be a reflection of that overwhelming demand.
The IPO received a massive 93.71x subscription, showcasing strong interest from across investor categories. The company mobilised ₹268.5 crore from anchors ahead of the issue.
The listing details reveal how the demand translated on listing day:
- NSE Listing: ₹730
- BSE Listing: ₹725
- IPO Price Band: ₹563–₹593
- IPO Size: ₹895 crore
- Total Market Cap Post Listing: ₹8,188.78 crore
Across both exchanges, the Sudeep Pharma share price debut held firm and above the issue price, confirming the strong appetite seen during bidding.
Sudeep Pharma IPO Details: Structure, Issue Size & Allocation
The public issue was a combination of fresh equity and an offer for sale. Each component contributed to the ₹895-crore total issue size.
Breakdown of the IPO
- Fresh Issue:
- 16 lakh shares
- Worth ₹95 crore
- Offer for Sale (OFS):
- 1.35 crore shares
- Worth ₹800 crore
Under the OFS, several promoter entities divested part of their holdings.
Important Facts for Investors
- Lot Size: 25 shares per lot
- Minimum Investment:
- Based on upper band ₹593 → ₹14,825 per lot
Use of Proceeds
The company has earmarked:
- ₹75.81 crore for capital expenditure, specifically for purchasing machinery for its production line at Nandesari Facility I in Gujarat.
- ₹12.67 crore for general corporate purposes.
These allocations highlight the focus on strengthening manufacturing capabilities.
Sudeep Pharma: What the Company Does
Sudeep Pharma operates in a specialised segment, serving the pharmaceutical, food, and nutrition industries. The company manufactures excipients and speciality ingredients that play a crucial role in product performance, stability, and quality.
Its portfolio is built for highly regulated industries, where consistency and precision matter. Over the years, the company has carved a strong presence across both Indian and global markets, serving as a reliable supplier of high-value functional ingredients.
Financial Performance: FY24 vs FY25
The company has shown steady growth year over year. The numbers reflect an expanding business backed by rising demand.
Key Financial Highlights
- Revenue:
- FY24: ₹459.28 crore
- FY25: ₹501.99 crore
- Growth: ~9.3%
- Total Assets:
- FY24: ₹513.86 crore
- FY25: ₹717.17 crore
- Growth: ~39.6%
- Net Profit:
- FY24: ₹133.18 crore
- FY25: ₹138.69 crore
- Growth: ~4.1%
The numbers show consistent revenue expansion, a substantial asset build-up, and stable profitability.
Company Details: A Growing Player in Speciality Ingredients
Sudeep Pharma has positioned itself as a technology-led manufacturer offering end-to-end solutions in excipients and formulation components. Its product suite adds value to pharmaceutical, food, and nutrition applications — industries that rely on strict adherence to global quality standards.
The company has also expanded its customer base steadily, building long-term relationships across domestic and international markets.
Summary
Sudeep Pharma's share price made a strong first impression on the Indian stock market today. With a 23% premium listing, an ₹8,188.78 crore market cap, and a heavily subscribed public issue at 93.71x, the listing day momentum reflects the confidence built during the IPO phase.
The company enters the market with clear growth numbers, expanding assets, and a focused strategy of strengthening manufacturing capabilities.
Its presence across critical sectors like pharma, nutrition, and food places it in a well-defined niche — and today’s listing reinforces the interest around its growth journey.
Easy & quick
Leave A Comment?